Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 25;10(1):e003747. doi: 10.1136/jitc-2021-003747

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Predictive immune parameters of treatment failure. Comparison of the histological parameters (A) intratumoral CD8 +cell density as determined by immunohistochemistry, (B) programmed cell death ligand 1 (PD-L1) tumor cell area (TC area), (C) PD-L1 immune cell area (IC area) and the liquid immune parameters (D) dendritic cells (DC; LIN-/HLA-DR+), (E) myeloid DCs (mDC; LIN-/HLA-DR+/CD11c high, CD1c-, CD123 low), (F) double negative T cells (DNT; CD3+/CD4-/CD8-), and (G) HLA-DR +B cells (CD19+/CD20+) in patients with locoregional tumor recurrence, residual locoregional disease or distant metastases (RRM) and without RRM (non-RRM). HLAD-DR, human leukocyte antigen – DR isotype.